ClinicalTrials.gg
CompletedNCT01984424GAUSS-3Updated Nov 29, 2018Results posted

Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-3

A Phase 3 interventional study of Atorvastatin and Placebo to Atorvastatin in Hyperlipidemia, sponsored by Amgen. Completed at 58 sites in 13 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2018-11-29.

Sponsored by Amgen · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
511
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies testing evolocumab in Hyperlipidemias — none open to participants now, none under way, none of them phase 3. evolocumab · Hyperlipidemias.

Enrollment
6th of 21
511 · median 307
Started
2013
with 6 others
Phase 3
12 of 21
none open now
Registered
11th of 21
by date
Lead sponsor
16 of 21
Amgen

Among the 21 studies testing evolocumab in Hyperlipidemias, this one is the 6th largest by enrollment, is one of 7 that started in 2013, is one of 12 in phase 3, and was the 11th registered.

Hyperlipidemias

862 studies on the registry are indexed under Hyperlipidemias; 109 are open to participants now.

Browse Hyperlipidemias studies →

Open to participants now

None of the 21 studies testing evolocumab in Hyperlipidemias is open now. The open studies under Hyperlipidemias, anywhere →

About evolocumab

evolocumab: first FDA approval 2015 (REPATHA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 67 Hyperlipidemias studies recruiting now, 27 (40%) set no upper age limit and 32 (48%) stop at 75 or younger; 8 take children under 18; 16 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 21 studies testing evolocumab in Hyperlipidemias as a file.
02

Study summary

The primary objective of this study was to evaluate the effect of 24 weeks of evolocumab administered subcutaneously (SC) every month, compared with ezetimibe, on low-density lipoprotein cholesterol (LDL-C) levels in adults with high cholesterol who are unable to tolerate an effective dose of a statin due to muscle-related side effects (MRSE).

Read the detailed description

The study is divided into 3 parts (A, B, C). After an initial 4-week washout period in which any statins, ezetimibe, or other lipid-lowering agents were discontinued, participants were enrolled in phase A, a double-blind, placebo-controlled crossover procedure to rechallenge patients with atorvastatin. Patients were randomly assigned in a 1:1 ratio to receive either atorvastatin (20 mg daily) or matching placebo for the first 10 weeks (period 1), then underwent a 2-week washout period, followed by crossover to the alternate therapy for a second 10-week period (period 2). Patients who experienced intolerable muscle symptoms during the first period did not complete the full 10 weeks of exposure but entered a 2-week washout period before proceeding to period 2.

Participants who did not develop muscle-related side effects were removed from the study, as were patients who reported muscle-related side effects during a placebo period.

After completion of phase A, patients who experienced muscle-related adverse effects while taking atorvastatin but not placebo were eligible for phase B, a 24-week, double-blind randomization to ezetimibe or evolocumab using a double-dummy design in which patients received either injectable placebo and oral ezetimibe or injectable evolocumab and oral placebo. A patient could proceed directly to phase B if they had a documented history of creatine kinase (CK) elevation more than 10 times the upper limit of normal accompanied by muscle symptoms while taking statin therapy, with documented resolution of both CK elevation and symptoms upon discontinuation of statin therapy.

These study procedures were designed to ensure that only patients with reproducible statin-associated muscle symptoms entered phase B of the study. For phase B, participants were randomized 2:1 to receive subcutaneously administered evolocumab (420 mg monthly) or oral ezetimibe (10 mg daily). Randomization in part B was stratified by screening LDL-C level (\< 180 mg/dL [4.66 mmol/L] vs. ≥ 180 mg/dL) at study baseline.

Participants who completed phase B and did not discontinue SC investigational product for any reason, including an adverse event, were eligible to proceed to the 2-year open-label extension phase C to evaluate the long-term safety and efficacy of evolocumab in statin-intolerant patients. Participants in phase C were allowed to choose quarterly between evolocumab 420 mg SC QM or evolocumab 140 mg SC every 2 weeks (Q2W).

03

Conditions studied

  • Hyperlipidemia

Keywords

  • High Cholesterol, Treatment for high cholesterol, Lowering cholesterol, Lowering high cholesterol, Hypercholesterolemia
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female ≥ 18 to ≤ 80 years of age
  • Subject not at LDL-C goal
  • History of statin intolerance
  • Lipid lowering therapy has been stable prior to enrolment for at least 4 weeks
  • Fasting triglycerides ≤ 400 mg/dL

Exclusion criteria

Exclusion Criteria:

  • (NYHA) III or IV heart failure
  • Uncontrolled cardiac arrhythmia
  • Uncontrolled hypertension
  • Type 1 diabetes
  • Poorly controlled type 2 diabetes
  • Uncontrolled hypothyroidism or hyperthyroidism
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
511 participants (actual)

Study arms

  • Other
    Part A: Atorvastatin 20 mg => Placebo

    Participants received atorvastatin 20 mg orally for 10 weeks (period 1) followed by placebo orally for 10 weeks (period 2), separated by a 2-week washout period.

    Drug: Atorvastatin · Drug: Placebo to Atorvastatin

  • Other
    Part A: Placebo => Atorvastatin 20 mg

    Participants received placebo orally for 10 weeks (period 1) followed by atorvastatin 20 mg orally for 10 weeks (period 2), separated by a 2-week washout period.

    Drug: Atorvastatin · Drug: Placebo to Atorvastatin

  • Active comparator
    Part B: Ezetimibe

    Participants received 10 mg ezetimibe orally only a day and placebo to evolocumab by subcutaneous injection once a month for 24 weeks.

    Drug: Ezetimibe · Other: Placebo to Evolocumab

  • Experimental
    Part B: Evolocumab

    Participants received 420 mg evolocumab by subcutaneous injection once a month and placebo to ezetimibe orally once a day for 24 weeks.

    Other: Placebo to Ezetimibe · Drug: Evolocumab

  • Experimental
    Part C: Open-label Evolocumab

    Participants who completed part B and were eligible to proceed to open-label extension part C and could choose quarterly between evolocumab 420 mg once a month or evolocumab 140 mg every 2 weeks for up to 2 years.

    Drug: Evolocumab

Interventions

  • Atorvastatin was supplied as over-encapsulated 20 mg tablets

    Also known as: Lipitor

  • DrugPlacebo to Atorvastatin

    Placebo matching to atorvastatin supplied as over-encapsulated tablets

  • OtherPlacebo to Ezetimibe

    Placebo matching to Ezetimibe supplied as over-encapsulated tablets.

  • Ezetimibe was supplied as 10 mg tablets, over-encapsulated for blinding.

    Also known as: Zetia

  • OtherPlacebo to Evolocumab

    Placebo matching to evolocumab supplied as single-use prefilled autoinjector/pen(s)

  • Evolocumab supplied as single-use prefilled autoinjector/pen(s)

    Also known as: Repatha

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in LDL-C at the Mean of Weeks 22 and 24

    Time frame: Baseline and weeks 22 and 24

  2. Percent Change From Baseline in LDL-C at Week 24

    Time frame: Baseline and week 24

Secondary outcomes

  1. Change From Baseline in LDL-C at the Mean of Weeks 22 and 24

    Time frame: Baselie and weeks 22 and 24

  2. Change From Baseline in LDL-C at Week 24

    Time frame: Baseline and week 24

  3. Percentage of Participants Who Achieved a Mean LDL-C at Weeks 22 and 24 of Less Than 70 mg/dL

    Time frame: Weeks 22 and 24

  4. Percentage of Participants Who Achieved LDL-C at Week 24 of Less Than 70 mg/dL

    Time frame: Week 24

  5. Percent Change From Baseline in Total Cholesterol at the Mean of Weeks 22 and 24

    Time frame: Baseline and weeks 22 and 24

  6. Percent Change From Baseline in Total Cholesterol at Week 24

    Time frame: Baseline and week 24

  7. Percent Change From Baseline in Non-high-density Lipoprotein Cholesterol (Non-HDL-C) at the Mean of Weeks 22 and 24

    Time frame: Baseline and weeks 22 and 24

  8. Percent Change From Baseline in Non-HDL-C at Week 24

    Time frame: Baseline and week 24

  9. Percent Change From Baseline in Apolipoprotein B at the Mean of Weeks 22 and 24

    Time frame: Baseline and weeks 22 and 24

  10. Percent Change From Baseline in Apolipoprotein B at Week 24

    Time frame: Baseline and week 24

  11. Percent Change From Baseline in Total Cholesterol/HDL-C Ratio at the Mean of Weeks 22 and 24

    Time frame: Baseline and weeks 22 and 24

  12. Percent Change From Baseline in Total Cholesterol/HDL-C Ratio at Week 24

    Time frame: Baseline and week 24

  13. Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at the Mean of Weeks 22 and 24

    Time frame: Baseline and Weeks 22 and 24

  14. Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at Week 24

    Time frame: Baseline and week 24

  15. Percent Change From Baseline in Lipoprotein(a) at the Mean of Weeks 22 and 24

    Time frame: Baseline and Weeks 22 and 24

  16. Percent Change From Baseline in Lipoprotein(a) at Week 24

    Time frame: Baseline and week 24

  17. Percent Change From Baseline in Triglycerides at the Mean of Weeks 22 and 24

    Time frame: Baseline and weeks 22 and 24

  18. Percent Change From Baseline in Triglycerides at Week 24

    Time frame: Baseline and week 24

  19. Percent Change From Baseline in High-density Lipoprotein Cholesterol (HDL-C) at Week 24

    Time frame: Baseline and weeks 22 and 24

  20. Percent Change From Baseline in HDL-C at Week 24

    Time frame: Baseline and week 24

  21. Percent Change From Baseline in Very Low-density Lipoprotein Cholesterol (VLDL-C) at the Mean of Weeks 22 and 24

    Time frame: Baseline and weeks 22 and 24

  22. Percent Change From Baseline in VLDL-C at Week 24

    Time frame: Baseline and week 24

07

Results

Posted Mar 13, 2018

Participant flow

A total of 511 participants were enrolled (492 in Part A and 19 directly in Part B) at 53 centers in the United States of America, Europe, Australia, New Zealand, Canada, and South Africa from December 2013 to November 2014. Results are reported for participants randomized in Part B. Part C was ongoing at the time of this analysis.

Participant flow — Overall Study
MilestoneEzetimibeEvolocumab
Started73145
Completed70138
Not completed37
Withdrew: Withdrawal by subject35
Withdrew: Sponsor decision01
Withdrew: Lost to follow-up01

Outcome measures

PrimaryPercent Change From Baseline in LDL-C at the Mean of Weeks 22 and 24
Time frame:
Baseline and weeks 22 and 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline in LDL-C at the Mean of Weeks 22 and 24
percent changeEzetimibeEvolocumab
Percent Change From Baseline in LDL-C at the Mean of Weeks 22 and 24-16.70 ± 1.91-54.50 ± 1.39
Statistical analysis
  • Ezetimibe vs Evolocumab · Repeated Measures Model · p = <0.0001 · Ls mean treatment difference: -37.79 · 95% CI -42.31 to -33.28Model includes treatment group, stratification factor (screening LDL-C), scheduled visit and interaction of treatment with scheduled visit.
PrimaryPercent Change From Baseline in LDL-C at Week 24
Time frame:
Baseline and week 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline in LDL-C at Week 24
percent changeEzetimibeEvolocumab
Percent Change From Baseline in LDL-C at Week 24-16.69 ± 2.11-52.76 ± 1.52
Statistical analysis
  • Ezetimibe vs Evolocumab · Repeated Measures Model · p = <0.0001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -36.07 · 95% CI -41.07 to -31.08Model includes treatment group, stratification factor (screening LDL-C), scheduled visit and interaction of treatment with scheduled visit.
SecondaryChange From Baseline in LDL-C at the Mean of Weeks 22 and 24
Time frame:
Baselie and weeks 22 and 24
Reported as:
Least squares mean · mg/dL
Change From Baseline in LDL-C at the Mean of Weeks 22 and 24
mg/dLEzetimibeEvolocumab
Change From Baseline in LDL-C at the Mean of Weeks 22 and 24-31.0 ± 3.8-106.8 ± 2.7
Statistical analysis
  • Ezetimibe vs Evolocumab · Repeated Measures Model · p = <0.0001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -75.8 · 95% CI -84.7 to -67.0Model includes treatment group, stratification factor (screening LDL-C), scheduled visit and interaction of treatment with scheduled visit.
SecondaryChange From Baseline in LDL-C at Week 24
Time frame:
Baseline and week 24
Reported as:
Least squares mean · mg/dL
Change From Baseline in LDL-C at Week 24
mg/dLEzetimibeEvolocumab
Change From Baseline in LDL-C at Week 24-31.2 ± 4.0-102.9 ± 2.9
Statistical analysis
  • Ezetimibe vs Evolocumab · Repeated Measures Model · p = <0.0001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -71.7 · 95% CI -81.3 to -62.2Model includes treatment group, stratification factor (screening LDL-C), scheduled visit and interaction of treatment with scheduled visit.
SecondaryPercentage of Participants Who Achieved a Mean LDL-C at Weeks 22 and 24 of Less Than 70 mg/dL
Time frame:
Weeks 22 and 24
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved a Mean LDL-C at Weeks 22 and 24 of Less Than 70 mg/dL
percentage of participantsEzetimibeEvolocumab
Percentage of Participants Who Achieved a Mean LDL-C at Weeks 22 and 24 of Less Than 70 mg/dL1.4 (0.3 to 7.7)29.9 (22.9 to 38.1)
Statistical analysis
  • Ezetimibe vs Evolocumab · Cochran-Mantel-Haenszel · p = <0.0001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Treatment difference: 28.5 · 95% CI 19.1 to 36.7Based on Cochran-Mantel Haenszel test stratified by the stratification factor (screening LDL-C).
SecondaryPercentage of Participants Who Achieved LDL-C at Week 24 of Less Than 70 mg/dL
Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved LDL-C at Week 24 of Less Than 70 mg/dL
percentage of participantsEzetimibeEvolocumab
Percentage of Participants Who Achieved LDL-C at Week 24 of Less Than 70 mg/dL0.0 (0.0 to 6.3)27.4 (20.1 to 36.1)
Statistical analysis
  • Ezetimibe vs Evolocumab · Cochran-Mantel-Haenszel · p = <0.0001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Treatment difference: 27.4 · 95% CI 17.7 to 36.1Based on Cochran-Mantel Haenszel test stratified by the stratification factor (screening LDL-C).
SecondaryPercent Change From Baseline in Total Cholesterol at the Mean of Weeks 22 and 24
Time frame:
Baseline and weeks 22 and 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Total Cholesterol at the Mean of Weeks 22 and 24
percent changeEzetimibeEvolocumab
Percent Change From Baseline in Total Cholesterol at the Mean of Weeks 22 and 24-11.43 ± 1.41-38.04 ± 1.03
Statistical analysis
  • Ezetimibe vs Evolocumab · Repeated Measures Model · p = <0.0001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -26.61 · 95% CI -29.95 to -23.27Model includes treatment group, stratification factor (screening LDL-C), scheduled visit and interaction of treatment with scheduled visit.
SecondaryPercent Change From Baseline in Total Cholesterol at Week 24
Time frame:
Baseline and week 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Total Cholesterol at Week 24
percent changeEzetimibeEvolocumab
Percent Change From Baseline in Total Cholesterol at Week 24-11.57 ± 1.52-36.64 ± 1.10
Statistical analysis
  • Ezetimibe vs Evolocumab · Repeated Measures Model · p = <0.0001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -25.08 · 95% CI -28.67 to -21.48Model includes treatment group, stratification factor (screening LDL-C), scheduled visit and interaction of treatment with scheduled visit.
SecondaryPercent Change From Baseline in Non-high-density Lipoprotein Cholesterol (Non-HDL-C) at the Mean of Weeks 22 and 24
Time frame:
Baseline and weeks 22 and 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Non-high-density Lipoprotein Cholesterol (Non-HDL-C) at the Mean of Weeks 22 and 24
percent changeEzetimibeEvolocumab
Percent Change From Baseline in Non-high-density Lipoprotein Cholesterol (Non-HDL-C) at the Mean of Weeks 22 and 24-14.38 ± 1.72-47.44 ± 1.25
Statistical analysis
  • Ezetimibe vs Evolocumab · Repeated Measures Model · p = <0.0001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -33.06 · 95% CI -37.12 to -28.99Model includes treatment group, stratification factor (screening LDL-C), scheduled visit and interaction of treatment with scheduled visit.
SecondaryPercent Change From Baseline in Non-HDL-C at Week 24
Time frame:
Baseline and week 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Non-HDL-C at Week 24
percent changeEzetimibeEvolocumab
Percent Change From Baseline in Non-HDL-C at Week 24-14.62 ± 1.83-45.72 ± 1.32
Statistical analysis
  • Ezetimibe vs Evolocumab · Repeated Measures Model · p = <0.0001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -31.10 · 95% CI -35.44 to -16.76Model includes treatment group, stratification factor (screening LDL-C), scheduled visit and interaction of treatment with scheduled visit.
SecondaryPercent Change From Baseline in Apolipoprotein B at the Mean of Weeks 22 and 24
Time frame:
Baseline and weeks 22 and 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Apolipoprotein B at the Mean of Weeks 22 and 24
percent changeEzetimibeEvolocumab
Percent Change From Baseline in Apolipoprotein B at the Mean of Weeks 22 and 24-11.42 ± 1.82-45.28 ± 1.31
Statistical analysis
  • Ezetimibe vs Evolocumab · Repeated Measures Model · p = <0.0001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -33.86 · 95% CI -38.15 to -29.58Model includes treatment group, stratification factor (screening LDL-C), scheduled visit and interaction of treatment with scheduled visit.
SecondaryPercent Change From Baseline in Apolipoprotein B at Week 24
Time frame:
Baseline and week 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Apolipoprotein B at Week 24
percent changeEzetimibeEvolocumab
Percent Change From Baseline in Apolipoprotein B at Week 24-11.74 ± 1.94-43.50 ± 1.40
Statistical analysis
  • Ezetimibe vs Evolocumab · Repeated Measures Model · p = <0.0001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -31.75 · 95% CI -36.35 to -27.16Model includes treatment group, stratification factor (screening LDL-C), scheduled visit and interaction of treatment with scheduled visit.
SecondaryPercent Change From Baseline in Total Cholesterol/HDL-C Ratio at the Mean of Weeks 22 and 24
Time frame:
Baseline and weeks 22 and 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Total Cholesterol/HDL-C Ratio at the Mean of Weeks 22 and 24
percent changeEzetimibeEvolocumab
Percent Change From Baseline in Total Cholesterol/HDL-C Ratio at the Mean of Weeks 22 and 24-11.48 ± 1.75-41.39 ± 1.27
Statistical analysis
  • Ezetimibe vs Evolocumab · Repeated Measures Model · p = <0.0001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -29.91 · 95% CI -34.06 to -25.77Model includes treatment group, stratification factor (screening LDL-C), scheduled visit and interaction of treatment with scheduled visit.
SecondaryPercent Change From Baseline in Total Cholesterol/HDL-C Ratio at Week 24
Time frame:
Baseline and week 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Total Cholesterol/HDL-C Ratio at Week 24
percent changeEzetimibeEvolocumab
Percent Change From Baseline in Total Cholesterol/HDL-C Ratio at Week 24-12.84 ± 1.85-40.04 ± 1.33
Statistical analysis
  • Ezetimibe vs Evolocumab · Repeated Measures Model · p = <0.0001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -27.20 · 95% CI -31.58 to -22.82Model includes treatment group, stratification factor (screening LDL-C), scheduled visit and interaction of treatment with scheduled visit.
SecondaryPercent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at the Mean of Weeks 22 and 24
Time frame:
Baseline and Weeks 22 and 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at the Mean of Weeks 22 and 24
percent changeEzetimibeEvolocumab
Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at the Mean of Weeks 22 and 24-11.86 ± 1.89-45.99 ± 1.36
Statistical analysis
  • Ezetimibe vs Evolocumab · Repeated Measures Model · p = <0.0001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -34.13 · 95% CI -38.59 to -29.67Model includes treatment group, stratification factor (screening LDL-C), scheduled visit and interaction of treatment with scheduled visit.
SecondaryPercent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at Week 24
Time frame:
Baseline and week 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at Week 24
percent changeEzetimibeEvolocumab
Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at Week 24-12.62 ± 1.97-44.60 ± 1.41
Statistical analysis
  • Ezetimibe vs Evolocumab · Repeated Measures Model · p = <0.0001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -31.98 · 95% CI -36.64 to -27.32Model includes treatment group, stratification factor (screening LDL-C), scheduled visit and interaction of treatment with scheduled visit.
SecondaryPercent Change From Baseline in Lipoprotein(a) at the Mean of Weeks 22 and 24
Time frame:
Baseline and Weeks 22 and 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Lipoprotein(a) at the Mean of Weeks 22 and 24
percent changeEzetimibeEvolocumab
Percent Change From Baseline in Lipoprotein(a) at the Mean of Weeks 22 and 24-1.63 ± 2.80-22.71 ± 2.03
Statistical analysis
  • Ezetimibe vs Evolocumab · Repeated Measures Model · p = <0.0001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -21.08 · 95% CI -27.65 to -14.51Model includes treatment group, stratification factor (screening LDL-C), scheduled visit and interaction of treatment with scheduled visit.
SecondaryPercent Change From Baseline in Lipoprotein(a) at Week 24
Time frame:
Baseline and week 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Lipoprotein(a) at Week 24
percent changeEzetimibeEvolocumab
Percent Change From Baseline in Lipoprotein(a) at Week 240.17 ± 3.05-21.06 ± 2.19
Statistical analysis
  • Ezetimibe vs Evolocumab · Repeated Measures Model · p = <0.0001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -21.24 · 95% CI -28.42 to -14.05Model includes treatment group, stratification factor (screening LDL-C), scheduled visit and interaction of treatment with scheduled visit.
SecondaryPercent Change From Baseline in Triglycerides at the Mean of Weeks 22 and 24
Time frame:
Baseline and weeks 22 and 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Triglycerides at the Mean of Weeks 22 and 24
percent changeEzetimibeEvolocumab
Percent Change From Baseline in Triglycerides at the Mean of Weeks 22 and 24-0.95 ± 3.94-5.39 ± 2.84
Statistical analysis
  • Ezetimibe vs Evolocumab · Repeated Measures Model · p = 0.37 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -4.44 · 95% CI -13.74 to 4.87Model includes treatment group, stratification factor (screening LDL-C), scheduled visit and interaction of treatment with scheduled visit.
SecondaryPercent Change From Baseline in Triglycerides at Week 24
Time frame:
Baseline and week 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Triglycerides at Week 24
percent changeEzetimibeEvolocumab
Percent Change From Baseline in Triglycerides at Week 24-1.07 ± 4.97-2.88 ± 3.54
Statistical analysis
  • Ezetimibe vs Evolocumab · Repeated Measures Model · p = 0.37 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -1.82 · 95% CI -13.64 to 10.01Model includes treatment group, stratification factor (screening LDL-C), scheduled visit and interaction of treatment with scheduled visit.
SecondaryPercent Change From Baseline in High-density Lipoprotein Cholesterol (HDL-C) at Week 24
Time frame:
Baseline and weeks 22 and 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline in High-density Lipoprotein Cholesterol (HDL-C) at Week 24
percent changeEzetimibeEvolocumab
Percent Change From Baseline in High-density Lipoprotein Cholesterol (HDL-C) at Week 241.66 ± 1.717.85 ± 1.24
Statistical analysis
  • Ezetimibe vs Evolocumab · Repeated Measures Model · p = 0.0083 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: 6.18 · 95% CI 2.15 to 10.22Model includes treatment group, stratification factor (screening LDL-C), scheduled visit and interaction of treatment with scheduled visit.
SecondaryPercent Change From Baseline in HDL-C at Week 24
Time frame:
Baseline and week 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline in HDL-C at Week 24
percent changeEzetimibeEvolocumab
Percent Change From Baseline in HDL-C at Week 242.90 ± 1.897.40 ± 1.36
Statistical analysis
  • Ezetimibe vs Evolocumab · Repeated Measures Model · p = 0.0083 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: 4.50 · 95% CI 0.02 to 8.98Model includes treatment group, stratification factor (screening LDL-C), scheduled visit and interaction of treatment with scheduled visit.
SecondaryPercent Change From Baseline in Very Low-density Lipoprotein Cholesterol (VLDL-C) at the Mean of Weeks 22 and 24
Time frame:
Baseline and weeks 22 and 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Very Low-density Lipoprotein Cholesterol (VLDL-C) at the Mean of Weeks 22 and 24
percent changeEzetimibeEvolocumab
Percent Change From Baseline in Very Low-density Lipoprotein Cholesterol (VLDL-C) at the Mean of Weeks 22 and 24-2.15 ± 3.22-6.81 ± 2.33
Statistical analysis
  • Ezetimibe vs Evolocumab · Repeated Measures Model · p = 0.37 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -4.65 · 95% CI -12.25 to 2.94Model includes treatment group, stratification factor (screening LDL-C), scheduled visit and interaction of treatment with scheduled visit.
SecondaryPercent Change From Baseline in VLDL-C at Week 24
Time frame:
Baseline and week 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline in VLDL-C at Week 24
percent changeEzetimibeEvolocumab
Percent Change From Baseline in VLDL-C at Week 24-2.66 ± 3.88-3.90 ± 2.78
Statistical analysis
  • Ezetimibe vs Evolocumab · Repeated Measures Model · p = 0.37 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -1.23 · 95% CI -10.45 to 7.98Model includes treatment group, stratification factor (screening LDL-C), scheduled visit and interaction of treatment with scheduled visit.

Adverse events

Collected over 6 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Evolocumab—9/145 (6.2%)80/145 (55.2%)
Ezetimibe—10/73 (13.7%)40/73 (54.8%)
Most frequent serious events
Showing 10 of 20
Most frequent serious events
EventEvolocumabEzetimibe
Angina pectorisCardiac disorders1/1452/73
Atrial fibrillationCardiac disorders2/1450/73
Acute myocardial infarctionCardiac disorders0/1451/73
Angina unstableCardiac disorders0/1451/73
Gastrointestinal angiodysplasiaGastrointestinal disorders0/1451/73
Urinary tract infectionInfections and infestations0/1451/73
Hip fractureInjury, poisoning and procedural complications0/1451/73
Back painMusculoskeletal and connective tissue disorders0/1451/73
Carotid artery stenosisNervous system disorders0/1451/73
NeuralgiaNervous system disorders0/1451/73
Most frequent other events
Showing 10 of 12
Most frequent other events
EventEvolocumabEzetimibe
MyalgiaMusculoskeletal and connective tissue disorders20/14516/73
NasopharyngitisInfections and infestations14/1452/73
HeadacheNervous system disorders10/1457/73
ArthralgiaMusculoskeletal and connective tissue disorders13/1451/73
Muscle spasmsMusculoskeletal and connective tissue disorders13/1455/73
Pain in extremityMusculoskeletal and connective tissue disorders13/1451/73
FatigueGeneral disorders12/1455/73
Back painMusculoskeletal and connective tissue disorders10/1455/73
ConstipationGastrointestinal disorders3/1454/73
DiarrhoeaGastrointestinal disorders6/1454/73

Baseline characteristics

Age, Continuous
Age, Continuous(years)EzetimibeEvolocumabTotal
Mean58.5 ± 9.459.0 ± 11.158.8 ± 10.5
Age, Customized
Age, Customized(Participants)EzetimibeEvolocumabTotal
< 65 years5292144
≥ 65 years215374
Sex: Female, Male
Sex: Female, Male(Participants)EzetimibeEvolocumabTotal
Female3967106
Male3478112
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)EzetimibeEvolocumabTotal
Hispanic or Latino022
Not Hispanic or Latino73143216
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)EzetimibeEvolocumabTotal
American Indian or Alaska Native000
Asian123
Black or African American336
Native Hawaiian or Other Pacific Islander000
White69138207
Other022
Stratification Factor: Screening Low-density Lipoprotein Cholesterol (LDL-C)
Stratification Factor: Screening Low-density Lipoprotein Cholesterol (LDL-C)(Participants)EzetimibeEvolocumabTotal
< 180 mg/dL214061
≥ 180 mg/dL52105157
LDL-C Concentation
LDL-C Concentation(mg/dL)EzetimibeEvolocumabTotal
Mean221.9 ± 70.2218.8 ± 73.1219.9 ± 72.0
Total Cholesterol Concentration
Total Cholesterol Concentration(mg/dL)EzetimibeEvolocumabTotal
Mean308.0 ± 73.8306.5 ± 75.4307.0 ± 74.7

8 further baseline measures are reported on the registry.

08

Study locations

58 sites
  • Research Site
    Beverly Hills, California 90211, United States
  • Research Site
    Huntington Beach, California 92648, United States
  • Research Site
    Los Angeles, California 90048, United States
  • Research Site
    San Pedro, California 90732, United States
  • Research Site
    Atlanta, Georgia 30322, United States
  • Research Site
    Sterling, Illinois 61081, United States
  • Research Site
    Kansas City, Kansas 66160, United States
  • Research Site
    Baltimore, Maryland 21201, United States
  • Research Site
    Towson, Maryland 21204, United States
  • Research Site
    Ann Arbor, Michigan 48106, United States
  • Research Site
    Rochester, Minnesota 55905, United States
  • Research Site
    Saint Louis, Missouri 63110, United States
  • Research Site
    New York, New York 10029, United States
  • Research Site
    Durham, North Carolina 27710, United States
  • Research Site
    Cleveland, Ohio 44195, United States
  • Research Site
    York, Pennsylvania 17405, United States
  • Research Site
    Charleston, South Carolina 29425, United States
  • Research Site
    Houston, Texas 77030, United States
  • Research Site
    Camperdown, New South Wales 2015, Australia
  • Research Site
    Woolloongabba, Queensland 4102, Australia
  • Research Site
    Ashford, South Australia 5035, Australia
  • Research Site
    Vancouver, British Columbia V5Z 1M9, Canada
  • Research Site
    Hamilton, Ontario L8L 2X2, Canada
  • Research Site
    London, Ontario N6A 4V2, Canada
  • Research Site
    Peterborough, Ontario K9J 0B2, Canada
  • Research Site
    Montreal, Quebec H2W 1R7, Canada
  • Research Site
    St-Charles-Borromee, Quebec J6E 6J2, Canada
  • Research Site
    Quebec, G1V 4M6, Canada
  • Research Site
    Hradec Kralove, 500 05, Czechia
  • Research Site
    Praha 2, 128 08, Czechia
  • Research Site
    Praha 4, 140 21, Czechia
  • Research Site
    Aarhus N, 8200, Denmark
  • Research Site
    Glostrup, 2600, Denmark
  • Research Site
    Nantes Cedex 1, 44093, France
  • Research Site
    Paris Cedex 13, 75651, France
  • Research Site
    Vénissieux, 69200, France
  • Research Site
    Berlin, 13353, Germany
  • Research Site
    Köln, 50937, Germany
  • Research Site
    München, 80638, Germany
  • Research Site
    Bologna, 40138, Italy
  • Research Site
    Cagliari, 09134, Italy
  • Research Site
    Cinisello Balsamo (MI), 20092, Italy
  • Research Site
    Ferrara, 44100, Italy
  • Research Site
    Perugia, 06129, Italy
  • Research Site
    Pisa, 56124, Italy
  • Research Site
    Amsterdam, 1105 AZ, Netherlands
  • Research Site
    Rotterdam, 3045 PM, Netherlands
  • Research Site
    Zwijndrecht, 3331 LZ, Netherlands
  • Research Site
    Christchurch, 8011, New Zealand
  • Research Site
    Oslo, 0373, Norway
  • Research Site
    Ålesund, 6003, Norway
  • Research Site
    Johannesburg, Gauteng 2157, South Africa
  • Research Site
    Midrand, Gauteng 1685, South Africa
  • Research Site
    Observatory, Western Cape 7925, South Africa
  • Research Site
    Parow, Western Cape 7505, South Africa
  • Research Site
    Birmingham, B15 2TH, United Kingdom
  • Research Site
    Glasgow, G12 8TA, United Kingdom
  • Research Site
    Newcastle upon Tyne, NE1 4LP, United Kingdom
09

References and documents

Publications

  • Cho L, Dent R, Stroes ESG, Stein EA, Sullivan D, Ruzza A, Flower A, Somaratne R, Rosenson RS. Persistent Safety and Efficacy of Evolocumab in Patients with Statin Intolerance: a Subset Analysis of the OSLER Open-Label Extension Studies. Cardiovasc Drugs Ther. 2018 Aug;32(4):365-372. doi: 10.1007/s10557-018-6817-7. PubMed 30073585 ↗
  • Schmidt AF, Carter JL, Pearce LS, Wilkins JT, Overington JP, Hingorani AD, Casas JP. PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2020 Oct 20;10(10):CD011748. doi: 10.1002/14651858.CD011748.pub3. PubMed 33078867 ↗
  • Nissen SE, Stroes E, Dent-Acosta RE, Rosenson RS, Lehman SJ, Sattar N, Preiss D, Bruckert E, Ceska R, Lepor N, Ballantyne CM, Gouni-Berthold I, Elliott M, Brennan DM, Wasserman SM, Somaratne R, Scott R, Stein EA; GAUSS-3 Investigators. Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial. JAMA. 2016 Apr 19;315(15):1580-90. doi: 10.1001/jama.2016.3608. PubMed 27039291 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2013 to primary completion in Nov 2015, 23 months.

Results were first posted in Mar 2018, 2 years 4 months after primary completion. A results delay was requested in Sep 2016.

Of 51 industry-sponsored phase 3 interventional studies under Hyperlipidemias, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 23 months is above that.

Counting every sponsor, half of 57 studies reached it within 18 months; a quarter within 11 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 8, 2013
First posted
Nov 14, 2013
StartActual
Dec 10, 2013
Primary completionActual
Nov 10, 2015
CompletionActual
Nov 21, 2017
Results delay requested
Sep 13, 2016
Results first posted
Mar 13, 2018
Last update
Nov 29, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 29, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01984424
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Nov 14, 2013
Start date
Dec 10, 2013
Primary completion
Nov 10, 2015
Completion
Nov 21, 2017
Results posted
Mar 13, 2018
Last update
Nov 29, 2018

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Evolocumab

Start the discussion